Chong Kun Dang of the Republic of Korea has entered a licensing deal for the distribution of a darbepoetin alfa biosimilar in the Gulf region.
Two companies have entered a commercialization deal for what they said would be the first darbepoetin alfa biosimilar distributed in the Persian Gulf. Darbepoetin alfa is intended for the treatment of anemia associated with chronic renal failure. In the United States, darbepoetin alfa is distributed as Aranesp, an originator product.
The biosimilar (Nesbell) is currently approved in the Republic of Korea and would be marketed by Menagen Pharmaceutical Industries in the 7-member Arab states of the Persian Gulf: Bahrain, Kuwait, Iraq, Oman, Qatar, Saudi Arabia, and the United Arab Emirates.
The other partner to the deal is Chong Kun Dang Pharmaceutical (CKD), of Republic of Korea. “Through this collaboration with CKD we are establishing our biosimilar footprint in Middle East and Africa markets and reaching more people living with severe chronic diseases. We aim to provide broad accesses to patients with unmet medical needs by leveraging Menagen’s local expertise and capabilities,” CKD said in a statement.
Menagen was described as a biomanufacturing facility based in Muscat, Oman, with plans to expand operations into agents for oncology, hematology, nephrology, and other various medicines. These would include biosimilars and orphan drugs.
Competitive Pricing in Biosimilars: How Adalimumab Could Shape the Industry
Published: October 29th 2024 | Updated: October 29th 2024Sophia Humphreys, PharmD, MHA, BCBBS, of Sutter Health notes that although initial adoption of adalimumab biosimilars remained low in 2023, competitive pricing pressures have already benefited patients and the health care sector.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Unifying Standards: The Need for Streamlined Biosimilar Development
October 22nd 2024At the 2024 GRx+Biosims conference, industry leaders and regulatory experts underscored the urgency of unifying global standards and simplifying the biosimilar development process, sharing insights on recent advancements and the necessity for greater collaboration between manufacturers and regulatory agencies.
IQVIA Webinar: Enhancing Regulatory Strategies for Biosimilars and Generics
October 14th 2024During a recent webinar, experts discussed critical regulatory aspects for generics and biosimilars, highlighting strategies for navigating complex approval processes, the importance of local market understanding, and the role of technology in enhancing submission efficiency.